Format

Send to

Choose Destination
Cancer Discov. 2014 Sep;4(9):998-1013. doi: 10.1158/2159-8290.CD-14-0001. Epub 2014 Jul 15.

Patient-derived xenograft models: an emerging platform for translational cancer research.

Author information

1
Centro Nacional de Investigaciones Oncológicas, Madrid; mhidalgo@cnio.es.
2
Katholieke Universiteit Leuven, Leuven, Belgium;
3
Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow;
4
Masaryk University, Brno, Czech Republic;
5
Royal College of Surgeons in Ireland, Dublin, Ireland;
6
Cambridge Cancer Centre, Cambridge;
7
Breakthrough Breast Cancer Unit, Institute of Cancer Sciences, University of Manchester, Manchester, United Kingdom;
8
University Medical Centre Groningen, Groningen;
9
The Netherlands Cancer Institute, Amsterdam, the Netherlands;
10
Oslo University Hospital, Oslo, Norway;
11
Institut Curie, Paris, France;
12
Vall d'Hebron Institute of Oncology;
13
Candiolo Cancer Institute - FPO IRCCS; and Department of Oncology, University of Torino, Candiolo, Torino, Italy.
14
Catalan Institute of Oncology-Bellvitge Biomedical Research Institute, L'Hospitalet de Llobregat, Barcelona, Spain;

Abstract

Recently, there has been an increasing interest in the development and characterization of patient-derived tumor xenograft (PDX) models for cancer research. PDX models mostly retain the principal histologic and genetic characteristics of their donor tumor and remain stable across passages. These models have been shown to be predictive of clinical outcomes and are being used for preclinical drug evaluation, biomarker identification, biologic studies, and personalized medicine strategies. This article summarizes the current state of the art in this field, including methodologic issues, available collections, practical applications, challenges and shortcomings, and future directions, and introduces a European consortium of PDX models.

SIGNIFICANCE:

PDX models are increasingly used in translational cancer research. These models are useful for drug screening, biomarker development, and the preclinical evaluation of personalized medicine strategies. This review provides a timely overview of the key characteristics of PDX models and a detailed discussion of future directions in the field.

PMID:
25185190
PMCID:
PMC4167608
DOI:
10.1158/2159-8290.CD-14-0001
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center